| Quantity: | |
|---|---|
Exemplar latitudinis librarium – Allergen (OVA, HDM, Fel d 1), adjuvant (LPS, c‑di‑GMP), et TSLP‑acti (MC903) exempla eosinophilica, neutrophilica, et mixta asthmatis endotypis granulocyticis.
Modi multiplices - C57BL/6, BALB/c, HIS humaniora, et IL4/IL4R transgenici mures in promptu sunt.
Fines comprehensivae — pondus corporis, AHR (Penh, resistentia), comites cellae BALF (eosinophilae, neutrophilae, macrophages), serum totalium IgE et allergene specifica IgE, cytokinum profiling (IL‑4, IL‑5, IL‑13, IL‑17), pulmonis histopathologia (HE, Masson, PAS), hematologia.
Valor translationalis – Idealis ad probationes biologicas (anti‑IL‑4Rα, anti‑IL‑5, anti‑IL‑13, anti‑TSLP, anti‑IL‑33), JAK inhibitores, corticosteroides et bronchodilatores.
IND‑parati fasciculi notati – Studia administrari possunt ad normam GLP principiorum.
OVA Asthma inductus exemplar in C57BL/6 Mures
OVA inductus Asthma Model in Balb / c Mures
OVA inductus asthma exemplar murium
OVA+MC903 Asthma exemplar inductum in C57BL/6 Mures
OVA+LPS Neutrophilic asthma Exemplar inductus in C57BL/6 Mures
HDM Suscepit Asthma exemplar in C57BL/6 Mures
HDM Suscepit Asthma Model in IL4/IL4R Mures
HDM+LPS Inductus Asthma Model in C57BL/6 Mures
HDM+MC903 Asthma exemplar inductum in C57BL/6 Mures
HDM + c-di-GMP Asthma exemplar inductum in C57BL/6 Mice
Fel d 1 Asthma Exemplar inductus in Balb/c Mures
• efficacia experimenti biologicorum (anti-IL-4Rα, anti-IL-5, anti-IL-13, anti-TSLP, anti-IL-33).
• Aestimatio inhibitores minoris moleculi (JAK inhibitores, PDE4 inhibitores, CRTH2 antagonistae)
• Target sanatio pro Th2, Th17, et epithelial-cytokini meatus
• Biomarker inventio (IgE, cytokina signatura, eosinophil/neutrophil venalicium)
• IND - pharmacologiam et toxicologiam studiis
Parameter |
Specificatio |
Species/Strain |
C57BL/6, BALB/c, SUA humaniora, IL4/IL4R transgenic |
modus inductionis |
OVA alum MC903 ± LPS; HDM ± LPS ± MC903 ± c‑di‑GMP; Fel d 1 + alum |
Studium durationis |
3-8 weeks (sensitization + provocatione augmenta) |
Clavis terminos |
Corpus pondus, AHR (invasive/non‑invasive), BALF cytologia (eosinophils, neutrophilis, macrophages), serum totalium IgE & allergen‑specifica IgE, cytokini gradus (IL‑4, IL‑5, IL‑13, IL‑17, IFN‑γ), pulmonis histopathologia (HE, Masson, PAS) cum scoring. |
| Positivum imperium | Dexamethasone aut anti-IL‑4Rα antibody available ut referat compositorum |
Data sarcina |
Rudis notitia, analysis nuntiationum, BALF cellulae comites, ELISA eventus, histologia labitur, munus data pulmonis, bioinformatica (libitum) |
Q: Quomodo eligo exemplar ius AD medicament
A: Pro eosinophilica (Th2‑high) asthma, OVA vel HDM exempla in BALB/c vel C57BL/6 commendantur. Ad exempla neutrophilica vel mixta granulocyticis asthma OVA+LPS vel HDM+c‑di‑GMP in C57BL/6 apta sunt. Eius mures humaniores sunt ideales ad probandum biologicos humanos speciales. IL4/IL4R mures transgenici aptae sunt studiis viae Th2. Nostra turma scientifica exemplum lectionis in scopo tuo specifico dirigere potest.
Q: Quid interest inter exempla inducta OVA et HDM?
A: OVA exemplar est allergen quod adjuvant ad sentiendum requirendum, robusta Th2 responsa producens. HDM est amet allergenum humanum allergenum continens protessiones quae immunitatem tum innatam et adaptivam movent, arctius imitantes humanam asthma pathogenesis allergicam.
Q: Potestne haec exempla adhiberi ad studia indeclinabilia?
A: Ita. Studia peragi possunt secundum principia GLP pro submissionibus moderantibus (FDA, EMA).
Q: Tu nativus studiorum protocolla praebes (exempli gratia, diversum sensum/provocationem schedulas, iuncturas therapias)?
A: Absolute. Nostrae turmae sartores scientificae inductionis protocolla, cedulas curationum, et analyses analysi ad specificum pharmacum candidatum.
Q: Quid est typicam timeline pro gubernator efficacia studio?
A: Pleraque asthma exempla intra 4-6 septimanas complentur, in quibus sensus, provocatio, curatio, analysis endpunctum.
